Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Tettero, Jesse M.
~ 100  Ergebnisse:
Personensuche X
?
1

Impact of hemodilution on flow cytometry based measurable r..:

Tettero, Jesse M. ; Heidinga, Maaike E. ; Mocking, Tim R....
Leukemia.  38 (2024)  3 - p. 630-639 , 2024
Link: https://doi.org/10.1038/..
 
?
2

Covering Hierarchical Dirichlet Mixture Models on binary da..:

Dall'Olio, Daniele ; Sträng, Eric ; Turki, Amin T....
PLOS Computational Biology.  20 (2024)  2 - p. e1011299 , 2024
Link: https://doi.org/10.1371/..
 
?
3

Prospective Validation of the Prognostic Relevance of CD34+..:

Ngai, Lok Lam ; Hanekamp, Diana ; Janssen, Fleur...
Blood.  , 2023
Link: https://doi.org/10.1182/..
 
?
4

Analytical assay validation for acute myeloid leukemia meas..:

Tettero, Jesse M. ; Dakappagari, Naveen ; Heidinga, Maaike E....
Cytometry Part B: Clinical Cytometry.  104 (2023)  6 - p. 426-439 , 2023
Link: https://doi.org/10.1002/..
 
?
5

Prognostic Significance of Measurable Residual Disease Dete..:

Tettero, Jesse M. ; Buisman, Yara ; Ngai, Lok Lam...
HemaSphere.  7 (2023)  12 - p. e981 , 2023
Link: https://doi.org/10.1097/..
 
?
6

Measurable residual disease-guided therapy in intermediate-..:

Tettero, Jesse M. ; Ngai, Lok Lam ; Bachas, Costa...
Haematologica.  , 2023
Link: https://doi.org/10.3324/..
 
?
7

Concordance in measurable residual disease result after fir..:

Tettero, Jesse M. ; Al-Badri, Waleed K. W. ; Ngai, Lok Lam...
Frontiers in Oncology.  12 (2022)  - p. , 2022
Link: https://doi.org/10.3389/..
 
?
8

Technical Aspects of Flow Cytometry-based Measurable Residu..:

Tettero, Jesse M. ; Freeman, Sylvie ; Buecklein, Veit...
HemaSphere.  6 (2022)  1 - p. e676 , 2022
Link: https://doi.org/10.1097/..
 
?
9

AML/Normal Progenitor Balance Instead of Total Tumor Load (..:

Hanekamp, Diana ; Tettero, Jesse M. ; Ossenkoppele, Gert J....
Cancers.  13 (2021)  11 - p. 2597 , 2021
Link: https://doi.org/10.3390/..
 
?
10

2021 Update on MRD in acute myeloid leukemia: a consensus d..:

Heuser, Michael ; Freeman, Sylvie D. ; Ossenkoppele, Gert J....
Blood.  138 (2021)  26 - p. 2753-2767 , 2021
Link: https://doi.org/10.1182/..
 
?
11

Measurable residual disease-guided therapy in intermediate-..:

Tettero, Jesse M ; Ngai, Lok Lam ; Bachas, Costa...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542837/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
12

Prognostic Significance of Measurable Residual Disease Dete..:

Tettero, Jesse M ; Buisman, Yara ; Ngai, Lok Lam...
https://boris.unibe.ch/189622/.  , 2023
Link: https://boris.unibe.ch/1..
 
?
13

Measurable residual disease-guided therapy in intermediate-..:

Tettero, Jesse M ; Ngai, Lok Lam ; Bachas, Costa...
https://boris.unibe.ch/181594/.  , 2023
Link: https://boris.unibe.ch/1..
 
?
14

Prospective validation of the prognostic relevance of CD34+..:

Ngai, Lok Lam ; Hanekamp, Diana ; Janssen, Fleur...
info:eu-repo/semantics/altIdentifier/doi/10.1182/blood.2022019160.  , 2023
Link: https://repository.vu.lt..
 
?
15

Concordance in measurable residual disease result after fir..:

Tettero, Jesse M ; Al-Badri, Waleed K W ; Ngai, Lok Lam...
info:eu-repo/semantics/altIdentifier/doi/10.3389/fonc.2022.999822.  , 2022
Link: https://repository.vu.lt..
 
1-15